Amgen Inc. (AMGN) stock prices updated...
Please, Signup (Login) to subscribe or trade (demo)
Amgen Inc. stock price
Amgen Inc. latest news:
U.S. FDA approves biosimilar version of cancer drug Avastin
Sept 14 (Reuters) - The U.S. Food and Drug Administration
said on Thursday it has approved Amgen Inc's biosimilar
version of Roche Holding AG's cancer drug Avastin.
UK Stocks-Factors to watch on Sept 7
Sept 7 (Reuters) - Britain's FTSE 100 index is seen opening 10
points higher at 7354.13 on Thursday, according to financial bookmakers.
* RBS: Britain's financial regulator should release a leaked report about
Royal Bank of Scotland that alleged many companies suffered from
"inappropriate action" by its Global Restructuring Group unit, a senior British
* ASTRAZENECA: A new kind of injectable biotech treatment for severe asthma
from AstraZeneca and Amgen promises t
BRIEF-FDA accepts Amgen's filing of a supplemental new drug application to add overall survival results to Kyprolis® ...
Amgen Inc(AMGN). * FDA accepts Amgen's(AMGN) filing of a supplemental new drug application to add overall survival results to Kyprolis® label. * Amgen Inc (AMGN) - FDA sets PDUFA target action date of April 30, 2018. * Amgen Inc (AMGN) - Adverse events observed in updated analysis were consistent with those previously reported for endeavor Source text for Eikon: Further company coverage:
Is the System Rigged Against Biosimilars?
Pfizer and Amgen are encountering problems getting traction for their biosimilars. Is the system rigged against them?
Amgen's cholesterol drug is cost-effective at $10,000 a year: study
Amgen Inc.'s cholesterol-lowering drug Repatha is cost-effective for high-risk patients at a yearly net price of $9,669 or below, according to a new study published in the medical journal JAMA Cardiology. The analysis used data from a trial enrolling patients with established atherosclerotic cardiovascular disease, which can cause a heart attack or stroke, and used rates of those events in a typical population. Repatha's list price is more than $14,500 a year; that price does not reflect often-substantial discounts. Repatha and other cholesterol-controlling PCSK9 drugs -- intended for patients whose cholesterol levels haven't been reduced sufficiently by lifestyle changes or statins -- haven't sold as well as expected, due to, in part, their high price tags. The new JAMA Cardiology study will likely play a role in price negotiations between health insurers, which have been extremely reluctant to cover drugs like Repatha, pharmacy-benefit managers and Amgen. Amgen shares weren't active in postmarket trade. Shares have surged 9.7% over the last three months, compared with a 1.9% rise in the S&P 500 .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Amgen shares down 3% after company's guidance on lower end of expectations
Shares of Amgen Inc. fell late Tuesday after the company beat per-share earnings expectations and sales forecasts but provided 2017 guidance on the low end of forecasts. The company said it earned $2.2 billion, or $2.91 a share, in the second quarter, compared with $1.9 billion, or $2.47 a share, in the year-ago period. Adjusted for one-time items, Amgen reported per-share earnings of $3.27, "driven by higher operating margins," it said in a statement. Revenues rose 2% to $5.8 billion, from $5.7 billion a year ago. Analysts polled by FactSet had expected adjusted earnings of $3.11 a share on sales of $5.7 billion. Shares ended the regular session down 0.1%. Amgen also tweaked its 2017 earnings guidance to between $10.79 a share and $11.37 a share and between $12.15 a share and $12.65 a share adjusted. Sales guidance was revised to a range of $22.5 billion and $23 billion. The analysts surveyed by FactSet had expected adjusted 2017 EPS of $12.49 on sales of $22.7 billion for the year. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
BRIEF-Amgen says FDA accepts biologics license application for Aimovig
* FDA accepts biologics license application for Aimovig™
Amgen (AMGN) Gets CRL for Osteoporosis Drug Evenity's BLA
Amgen Inc AMGN and partner UCB SA UCBJF announced that the FDA has issued a complete response letter CRL for the biologics license application BLA for Evenity romosozumab Amgen is looking to get Evenity approved for the treatment of postmenopausal women with osteoporosis The
BRIEF-Amgen says second phase 3 study shows kyprolis regimen significantly improves overall survival in patients with ...
Amgen Inc(AMGN). * Second phase 3 study shows Kyprolis regimen significantly improves overall survival in patients with relapsed multiple myeloma. * Amgen Inc(AMGN) - adverse events observed in updated analysis were consistent with those previously reported for Aspire. * Amgen Inc (AMGN) - study met key secondary endpoint.
BRIEF-Amgen says second phase 3 study shows kyprolis regimen significantly improves overall survival in patients with relapsed multiple myeloma
* Second phase 3 study shows Kyprolis (carfilzomib) regimen
significantly improves overall survival in patients with
relapsed multiple myeloma
Amicus Therapeutics, Inc.FOLD
Amkor Technology, Inc.AMKR
Amphastar Pharmaceuticals, Inc.AMPH
Amtech Systems, Inc.ASYS
AmTrust Financial Services, Inc.AFSI
Anacor Pharmaceuticals, Inc.ANAC